Status In progress
Process STA
ID number 939

Provisional Schedule

Expected publication 06 December 2017

Project Team

Project lead Joanne Ekeledo

Email enquiries

Consultees

Companies sponsors Roche
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer
  Fight Bladder Cancer
Professional groups British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  Urology Foundation

Commentators

Comparator companies Accord Healthcare (carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Actavis UK (docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Dr Reddy's Laboratories (docetaxel) (CAU not returned, not participating)
  Eli Lilly (gemcitabine) (CAU not returned, not participating)
  Hospira (carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Medac (docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Sanofi (docetaxel) (CAU not returned, not participating)
  Seacross Pharmaceuticals (docetaxel) (CAU not returned, not participating)
  Sun Pharmaceuticals UK Ltd (carboplatin, gemcitabine) (CAU not returned, not participating)
  Peckforton Pharmaceuticals (paclitaxel) (CAU not returned, not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 November 2017 - 15 November 2017 Final appraisal determination
25 September 2017 The scope for this technology appraisal also includes atezolizumab for treating locally advanced or metastatic urothelial carcinoma in people whose disease has progressed after platinum-containing chemotherapy. More evidence for this group became available after the original committee discussion, so a separate document (and subsequent guidance) will be developed for this population when this evidence has been considered.
30 August 2017 Committee meeting: 2
02 August 2017 - 23 August 2017 Appraisal consultation: 1
17 May 2017 As the Committee for Medicinal Products for Human Use (at European Medicines Agency) has not yet given its opinion for the technology, we are not in a position to be able to release any documentation following the committee meeting on 26 April 2017. We will provide an update on the timings for documentation release and next steps in due course.
26 April 2017 Committee meeting: 1
09 November 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance